Pharmaniaga anticipates stronger earnings due to rising insulin demand, highlighting its vital role in Malaysia's pharmaceutical supply chain.
Pharmaniaga posts weaker earnings but retains positive outlook as manufacturing strengthens and financials improve ahead of FY26 biopharma rollout.
Pharmaniaga completes regularisation, boosts logistics capacity, and eyes biopharma growth with halal-certified insulin as a potential key revenue driver.
This website uses cookies.